Clinical trials: All-comers, open to volunteers
CAD - Coronary Artery Disease
REgistry of Paclitaxel Coated Drug Eluting Balloon in All Comers PaTients
A post marketing, observational , multi centre, prospective registry to assess safety and performance of the Drug Eluting Balloon in patients undergoing percutaneous coronary intervention.
- Trial name
- REPEAT (NCT06899555)
- Volunteers
- 500 people
- Sponsor
- Craigavon Area Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined conversion therapy strategy for patients with initially unresectable hepatocellular carcinoma (HCC).The primary…
- Trial name
- NCT07368023
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Coronary Artery Disease
The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient…
- Trial name
- PIONEER-IV (NCT04923191)
- Testing
- Angiography-derived physiology guidance/Local routine diagnostic procedure (LRDP) and usual care
- Where
- 19 sites in Belgium, Ireland and 3 more
- Volunteers
- 2,540 people
- Sponsor
- National University of Ireland, Galway, Ireland
Coronary Artery Disease
BioFreedom Ultra Registry
Over the past three decades, coronary stent struts have been made progressively thinner. Thin strut drug-eluting stents (DES) performed better than their thicker counterparts in a recent study.
- Trial name
- NCT05094284
- Testing
- BioFreedom Ultra
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma, Liver Transplantation
A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Hepatocellular Carcinoma Beyond UCSF Criteria Before Liver Transplantation
This is a single-center, retrospective cohort study aiming to evaluate the safety and efficacy of a combined treatment strategy for patients with hepatocellular carcinoma (HCC) who are beyond the UCSF criteria but intended for…
- Trial name
- NCT07310836
- Testing
- Locoregional Therapy (LRT) + Systemic Drug Therapy
- Volunteers
- 300 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Coronary Artery Disease
Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent…
- Trial name
- NOVA (NCT07566091)
- Testing
- Sirolimus-Ascorbic Acid Eluting Stent, Everolimus-Eluting Stent
- Where
- South Korea
- Volunteers
- 2,034 people
- Sponsor
- Jung-min Ahn
Calcific Coronary Arteriosclerosis
Prospective Registry on Intravascular Lithotripsy
multicenter, international, all-comers registry aims to provide insights in the current application of IVL technology in patients with calcified coronary lesions undergoing PCI using IVL technology.
- Trial name
- BENELUX-IVL (NCT06577038)
- Testing
- PCI with use of IVL
- Where
- 8 sites in Belgium, Greece and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Leiden University Medical Center
Hyperlipidemia, Cardio Vascular Disease
Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
- Trial name
- REDUCE-Lipid (NCT07311941)
- Where
- Hong Kong
- Volunteers
- 1,000 people
- Sponsor
- Chinese University of Hong Kong
Peripheral Artery Disease
Acotec DCB Post Market Clinical Follow-up
All-comers, prospective, multi-center, single-arm, non-interventional post market clinical follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 - Critical Limb Ischemia: Rutherford Clinical…
- Trial name
- FLOWER (NCT04393389)
- Testing
- AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
- Where
- 7 sites in Germany
- Volunteers
- 3,000 people
- Sponsor
- Acotec Scientific Co., Ltd